Acurx Pharmaceuticals LLC

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Acurx Pharmaceuticals excels in Q1, eyes partnerships and funding

Acurx Pharmaceuticals showcased strong performance in Q1 2024 with positive data, successful FDA outcomes, and robust Phase III trial preparations.
While facing challenges in costs, timelines, and partnership negotiations, the company remains optimistic about its future prospects and strategic opportunities.
Strategic partnerships, regulatory advancements, and potential funding from the PASTEUR Act present avenues for growth and development in Acurx's antibiotic pipeline.
Overall, Acurx Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges effectively, and leverage opportunities for continued success.

Acurx Pharmaceuticals progresses ibezapolstat towards Phase III trials

Acurx Pharmaceuticals is advancing ibezapolstat towards Phase III trials for C. difficile infection treatment
Despite financial challenges, the company is actively seeking partnerships and funding opportunities
The successful Phase II meeting with the FDA and new patent grant are key milestones for Acurx
Optimism surrounds the potential impact of ibezapolstat on improving C. difficile treatment

Acurx Pharmaceuticals reports Q3 loss, eyes growth through innovation and partnerships

Acurx Pharmaceuticals faces challenges in addressing potential dilution concerns and providing detailed insights into regulatory initiatives and Phase III trials. However, the company's strong pipeline, successful FDA meeting, and focus on innovation position it well for growth and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevation Oncology

GH Research PLC

Graphite Bio

Mister Car Wash

Alpha Teknova

Missfresh Ltd

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

7 Companies Go Public Today. What Investors Need to Know.

STATEN ISLAND, N.Y., June 25, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the pricing of an underwritten initial public offering of 2,500,000 newly-issued shares of its common stock at a price of $6.00 per share.

Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock

News for Acurx Pharmaceuticals LLC Stock (ACXP)